|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In ALDH<sup>+</sup>CD24<sup>-</sup>CD44<sup>+</sup> BCSCs, we identified P4HA2, PTGR1 and RAB40B as potential prognostic markers, which were virtually related to the status of BCSCs and tumor growth in TNBC cells.
|
29471829 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
FXR was expressed in 48 of 59 esophageal adenocarcinoma tissues (81.3%), and this overexpression was associated with higher tumor grade, larger tumor size, and lymph node metastasis; however, was inversely associated with retinoic acid receptor-β2 (RAR-β2 ) expression.
|
23280144 |
2013 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Aberrant promoter methylation of tumor suppressor genes including retinoic acid receptor-β2 (RAR-β2) is frequently detected in hepatitis C virus (HCV)-associated hepatocellular carcinoma; however, the mechanism and its significance are relatively unknown.
|
23474497 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Five lines of evidence suggest that melatonin works via epigenetic processes: (1) melatonin influences transcriptional activity of nuclear receptors (ERalpha, GR and RAR) involved in the regulation of breast cancer cell growth; (2) melatonin down-regulates the expression of genes responsible for the local synthesis or activation of estrogens including aromatase, an effect which may be mediated by methylation of the CYP19 gene or deacetylation of CYP19 histones; (3) melatonin inhibits telomerase activity and expression induced by either natural estrogens or xenoestrogens; (4) melatonin modulates the cell cycle through the inhibition of cyclin D1 expression; (5) melatonin influences circadian rhythm disturbances dependent on alterations of the light/dark cycle (i.e., light at night) with the subsequent deregulation of PER2 which acts as a tumor suppressor gene.
|
18592373 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical analysis of RARbeta protein in 15 breast carcinoma patients harboring unmethylated RAR bin tumors and serum DNA showed the expression of RARbeta protein in tumors and paired normal breast tissues, confirming the MSP findings, suggesting that RARbeta promoter is functional in these cases.
|
17998817 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We could also provide evidence that poorly differentiated grade 3 tumors had significantly higher RAR beta2 expression and lower methylation levels (p<0.05) than better differentiated grade 1 and grade 2 tumors.
|
17549354 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RAR-beta2, one of three human RAR-beta isoforms (RAR-beta1, RAR-beta2, RAR-beta4), is silenced in many tumors and acts as a tumor suppressor.
|
17608728 |
2007 |
|
Acute Promyelocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The NPM-RAR fusion protein associated with the t(5;17) variant of APL does not interact with PML.
|
16504291 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Quantitative methylation-specific PCR (qMSP) was performed using a selected tumor-related gene panel for RAR-ss2, MGMT, RASSF1A, and APC.
|
17108214 |
2006 |
|
Acute Promyelocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Regulation of CYP26A1 expression by selective RAR and RXR agonists in human NB4 promyelocytic leukemia cells.
|
15896339 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RAR-beta2 re-expression causes reversal of transformation, cell cycle arrest, and restoration of retinoid sensitivity.RAR-beta2 is thus a tumor suppressor.
|
15766561 |
2005 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Hypermethylation of the CDH1 was significantly associated with primary breast tumors demonstrating lymphovascular invasion (P = 0.008), infiltrating ductal histology (P = 0.03), and negative for the estrogen receptor (P = 0.005), whereas RASSF1A and RAR-beta2 gene hypermethylation were significantly more common in estrogen receptor-positive (P < 0.001) and human epidermal growth factor receptor 2-positive (P < 0.001) tumors, respectively.
|
15788661 |
2005 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We examined the tumor and the matched urine and serum DNA for aberrant methylation of nine gene promoters (CDH1, APC, MGMT, RASSF1A, GSTP1, p16, RAR-beta2, and ARF) from 17 patients with primary kidney cancer by quantitative fluorogenic real-time PCR.
|
15289362 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of the three RAR receptors (alpha, beta, and gamma), RARbeta has been considered a tumor suppressor gene.
|
15604252 |
2004 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The RAR-beta2 gene from non-neoplastic cervical tissues was mostly unmethylated and expressed, but methylated alleles of the gene were found in three samples of the morphologically normal tissues adjacent to the tumors.
|
11945179 |
2002 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Indeed, subsequent basic and clinical studies showed that chromosomal translocation involving the RARalpha gene is the cytogenetic hallmark of APL and that these mutant forms of RARs are the oncogenes in APL that interfere with the proliferation and differentiation pathways controlled by both RAR and their fusion partners.
|
11704848 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A growing body of evidence supports the hypotheses that retinoic acid receptor beta2 (RAR beta2) is a tumor suppressor gene.
|
11141504 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A growing body of evidence supports the hypothesis that the retinoic acid receptor beta2 (RAR-beta2) gene is a tumor suppressor gene which induces apoptosis and that the chemopreventive and therapeutic effects of retinoids are due to induction of RAR-beta2.
|
11501579 |
2001 |
|
Acute Promyelocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that the NPM-RAR fusion proteins can modulate expression of retinoid-responsive genes in a positive or negative manner, depending on context of the promoter, and lend support to the hypothesis that aberrant transcriptional activation underlies the APL phenotype.(Blood.2000;95:2683-2690)
|
10753851 |
2000 |
|
Acute Promyelocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the NB4 model of acute promyelocytic leukemia (APL), ATRA, 9-cis retinoic acid (9-cis RA), the pan-RAR and RARalpha-selective agonists, TTNPB and AM580, induce growth inhibition, granulocytic differentiation and apoptosis.
|
10800078 |
2000 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A growing body of evidence supports the hypotheses that the retinoic acid receptor beta2 (RAR-beta2) gene is a tumor suppressor gene and that the chemopreventive effects of retinoids are due to induction of RAR-beta2.
|
10814678 |
2000 |
|
Acute Promyelocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia.
|
9657734 |
1998 |
|
Acute Promyelocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
From the normal allele, both RAR alpha1 and RAR alpha2 mRNAs were expressed in all APL cases (N = 24).
|
9207466 |
1997 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The RARA sequences are the same as the RARA sequences found in the PML-RAR and PLZF-RAR fusion seen in t(15;17) and t(11;17) APL, respectively.
|
8562957 |
1996 |